These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34084119)

  • 1. Intravesical docetaxel for high-risk non-muscle invasive bladder cancer after Bacillus Calmette-Guérin failure.
    Shantharam G; Amin A; Pereira J; Kott O; Mueller-Leonhard C; Mega A; Golijanin D; Gershman B
    Curr Urol; 2021 Mar; 15(1):33-38. PubMed ID: 34084119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer.
    McElree IM; Steinberg RL; Mott SL; O'Donnell MA; Packiam VT
    JAMA Netw Open; 2023 Feb; 6(2):e230849. PubMed ID: 36853609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.
    Steinberg RL; Thomas LJ; Brooks N; Mott SL; Vitale A; Crump T; Rao MY; Daniels MJ; Wang J; Nagaraju S; DeWolf WC; Lamm DL; Kates M; Hyndman ME; Kamat AM; Bivalacqua TJ; Nepple KG; O'Donnell MA
    J Urol; 2020 May; 203(5):902-909. PubMed ID: 31821066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy.
    Yim K; Melnick K; Mott SL; Carvalho FLF; Zafar A; Clinton TN; Mossanen M; Steele GS; Hirsch M; Rizzo N; Wu CL; Mouw KW; Wszolek M; Salari K; Feldman A; Kibel AS; O'Donnell MA; Preston MA
    Urol Oncol; 2023 Nov; 41(11):458.e1-458.e7. PubMed ID: 37690933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
    Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and Preclinical Therapies for Bladder Cancer Following Bacillus Calmette-Guérin Failure.
    Nazmifar M; Williams C; Naser-Tavakolian A; Heard J; Rosser C; Theodorescu D; Ahdoot M
    J Urol; 2023 Jan; 209(1):32-48. PubMed ID: 36067380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative sarcopenia and systemic immune-inflammation index can predict response to intravesical Bacillus Calmette-Guerin instillation in patients with non-muscle invasive bladder cancer.
    Liu P; Chen S; Gao X; Liang H; Sun D; Shi B; Zhang Q; Guo H
    Front Immunol; 2022; 13():1032907. PubMed ID: 36225922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy.
    Barlow LJ; McKiernan JM; Benson MC
    J Urol; 2013 Mar; 189(3):834-9. PubMed ID: 23123371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer.
    Chevuru PT; McElree IM; Mott SL; Steinberg RL; O'Donnell MA; Packiam VT
    Urol Oncol; 2023 Mar; 41(3):148.e1-148.e7. PubMed ID: 36456454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early experience with sequential intravesical gemcitabine and docetaxel for micropapillary variant non-muscle invasive bladder cancer.
    Abou Chakra M; McElree IM; Packiam VT; Mott SL; O'Donnell MA
    Urol Oncol; 2024 Sep; 42(9):289.e13-289.e21. PubMed ID: 38796357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy.
    Barlow L; McKiernan J; Sawczuk I; Benson M
    BJU Int; 2009 Oct; 104(8):1098-102. PubMed ID: 19389012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
    Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A Randomized Controlled Study of Intravesical Instillation Therapy of Bacillus Calmette-Guérin vs. Epirubicinin Treating Non-muscular Invasive Bladder Cancer].
    Yang WX; Shao YX; Hu X; Xiong SC; Liu Y; Li X
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Mar; 52(2):326-333. PubMed ID: 33829710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer.
    Steinberg RL; Thomas LJ; O'Donnell MA; Nepple KG
    Bladder Cancer; 2015 Apr; 1(1):65-72. PubMed ID: 30561441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.
    Sfakianos JP; Kim PH; Hakimi AA; Herr HW
    J Urol; 2014 Feb; 191(2):341-5. PubMed ID: 23973518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer.
    Tan WS; McElree IM; Davaro F; Steinberg RL; Bree K; Navai N; Dinney CP; O'Donnell MA; Li R; Kamat AM; Packiam VT
    Eur Urol Oncol; 2023 Oct; 6(5):531-534. PubMed ID: 37468392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.
    Fujita N; Hatakeyama S; Momota M; Kido K; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2020 Aug; 38(8):684.e17-684.e24. PubMed ID: 32278732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative abdominal fat distribution and systemic immune inflammation were associated with response to intravesical Bacillus Calmette-Guerin immunotherapy in patients with non-muscle invasive bladder cancer.
    Ke ZB; Chen H; Chen JY; Cai H; Lin YZ; Sun XL; Huang JB; Zheng QS; Wei Y; Xue XY; Xu N
    Clin Nutr; 2021 Dec; 40(12):5792-5801. PubMed ID: 34775222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction and maintenance of sequential intravesical gemcitabine/docetaxel for intermediate and high-risk non-muscle invasive bladder cancer with different dosage protocols.
    Ben-David R; Tillu N; Alerasool P; Bieber C; Ranti D; Tolani S; Eisenhauer J; Chung R; Lavallée E; Waingankar N; Attalla K; Wiklund P; Mehrazin R; Anderson CB; Sfakianos JP
    World J Urol; 2024 May; 42(1):315. PubMed ID: 38734774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.